Frovatriptan drug interactions: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
|||
| Line 12: | Line 12: | ||
Because their vasospastic effects may be additive, co-administration of FROVA and other 5-HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated [see Contraindications (4)]. | Because their vasospastic effects may be additive, co-administration of FROVA and other 5-HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated [see Contraindications (4)]. | ||
===Selective | ===Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome=== | ||
Cases of [[Serotonin]] syndrome have been reported during combined use of triptans and [[SSRIs]], [[SNRI]]s, TCAs, and [[MAO]] inhibitors [see Warnings and Precautions (5.7)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0703630-9ce8-4259-841e-71fd2019fa66 | publisher = | date = | accessdate = | Cases of [[Serotonin]] syndrome have been reported during combined use of triptans and [[SSRIs]], [[SNRI]]s, TCAs, and [[MAO]] inhibitors [see Warnings and Precautions (5.7)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0703630-9ce8-4259-841e-71fd2019fa66 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
{{Reflist | {{Reflist}} | ||
{{FDA}} | |||
[[Category:Antimigraine drugs]] | |||
[[Category:Triptans]] | [[Category:Triptans]] | ||
[[Category: | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 22:29, 9 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Drug Interactions
Ergot-containing Drugs
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other is contraindicated [see Contraindications (4)].
HT1B/1D Agonists
Because their vasospastic effects may be additive, co-administration of FROVA and other 5-HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated [see Contraindications (4)].
Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome
Cases of Serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)].[1]
References
Adapted from the FDA Package Insert.